24 August 2017 (Thursday) - Oncologist Newsletter

The Oncologist’s newsletter appeared in my inbox today. Maybe not immediately relevant to me, but interesting nonetheless…

Featured Articles

 

Current Treatments for Surgically Resectable, Limited‐Stage, and Extensive‐Stage Small Cell Lung Cancer

Thomas E. Stinchcombe

 

This review article provides an update on the standard therapies for surgically resected limited‐stage small cell lung cancer and extensive‐stage small cell lung cancer that have been investigated in recent clinical trials.

In the News   Studies Highlight ‘Potential New Targets for Immunotherapy’   New Targets for Drugs to Treat Fatty Liver Disease and Liver Cancer   NICE Decision Following EU Licensing for Kisqali Awaited

CME Activities

Advanced Prostate Cancer: Applying New Evidence from ASCO 2017 Faculty: A. Oliver Sartor, MD 0.5 AMA PRA Category 1 Credits™   Begin Activity     Treatment Selection and Sequencing in NSCLC: Perspectives from ASCO 2017 Faculty: Nathan Pennell, MD, PhD 0.5 AMA PRA Category 1 Credits™   Begin Activity

Clinical Trial Results   Prolonged Pemetrexed Infusion Plus Gemcitabine in Refractory Metastatic Colorectal Cancer: Preclinical Rationale and Phase II Study Results   Lessons Learned   > Difficulties in translating in vitro results into clinical practice are inevitable.   > Further efforts to verify the efficacy of alternative schedules of pemetrexed in solid tumors are encouraged.